Get Access To Every Broadway Story Unlock access to every one of the hundreds of articles published daily on BroadwayWorld by logging in with one click. Written in a user-friendly format and ...

THROMBOLEX™, Inc. presented the prespecified interim analysis from the first 50 patients in RAPID-PE, a prospective, multicenter U.S. study evaluating On-The-Table (OTT) pharmaco-mechanical lysis (PML ...

WESTMINSTER, Colo.--(BUSINESS WIRE)--Surefire Medical, Inc. today announced that the company’s new Precision targeted delivery infusion system, for direct-to-tumor embolization procedures, has ...

A multidisciplinary team with representatives from the departments of medicine, critical care, nursing, health care information systems (HIS), and pharmacy was formed to address the feasibility of ...

At the 2025 European Association for the Study of Diabetes (EASD) meeting in Vienna, investigators reported one-year outcomes from FORWARD, a pivotal study of zimislecel (VX-880), an allogeneic, stem ...

MANHATTAN, Kan. (WIBW) - The out-patient clinic at Ascension Via Christi in Manhattan treated seven patients Thursday with COVID-19 antibody infusions, in hopes to reduce the severity of symptoms.

Commonwealth Health Wilkes-Barre General Hospital held an open house in February to introduce its new outpatient infusion department. The 3,500-square-foot area on the hospital’s second floor has been ...

TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, is ...

Patients with weak heart function who receive stem cell therapy shortly after a heart attack are at lower risk of developing heart failure and related hospital stays compared with standard care, finds ...

Study design: Retrospective single centre study. Objectives: To evaluate a low-dose radioisotope imaging procedure for assessment of implanted intrathecal drug delivery and to compare the radiation ...

Credit: Getty Images. Lantidra is an allogeneic pancreatic islet cellular therapy. The Food and Drug Administration (FDA) has approved Lantidra (donislecel-jujn) for the treatment of type 1 diabetes ...